Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services

• Domainex is the first CRO to have installed the eProtein Discovery system

• Installation of Nuclera’s technology expands Domainex’s protein production services

Cambridge, UK, 04 November 2024 / Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, and Domainex, a multi-award winning provider of integrated, pre-clinical drug discovery services, today announced that Domainex is the first contract research organization (CRO) to have installed the eProtein Discovery system and offer protein production services using the technology.

Domainex provides a complete range of pre-clinical drug discovery services from protein production to medicinal chemistry for lead optimization. Installing eProtein Discovery expands Domainex’s service offering and enhances the company’s protein production workflows. Working with Domainex, more researchers will benefit from eProtein Discovery, supporting Nuclera’s mission to better human health by enabling scientists to easily access the proteins they need for their drug discovery research. For companies that are not yet ready or able to invest in the instrument, this provides another route to access the technology.

Nuclera’s eProtein Discovery system is designed to speed up protein expression and purification optimization in research labs, particularly those using AI including ML for protein design. Applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery enables rapid, scalable access to high-quality proteins, supporting both cell-free and cell-based expression methods. The system significantly reduces time and cost of these processes by automating construct screening, protein scale-up, and producing purified proteins for downstream functional testing in under 48 hours. The system accelerates workflows, achieving results in days rather than the months required by traditional cell-based methods.

Joseph Bertelsen, Chief Commercial Officer, Nuclera, commented: “We are excited to have trusted protein experts like Domainex as our first CRO Partner assisting us in making eProtein Discovery accessible to scientists worldwide. The eProtein Discovery™ system is poised to transform the landscape of protein research, making it an essential tool for anyone involved in the science of proteins. This installation reaffirms Nuclera’s commitment to accelerating discovery through easy and fast protein production, ensuring every protein project begins on eProtein Discovery™.”

Natalie Winfield, Executive Vice President, Commercial Operations, Domainex, added: “We are delighted to be the first CRO to offer a protein production service via the eProtein Discovery™ system. At Domainex, we are constantly evolving our service offering, ensuring that we have the latest and most innovative technologies, so we can apply optimal approaches to our clients’ drug discovery programs.”  

ENDS

For further information, please contact:

Nuclera media contact:
Dr Ben Rutter
Zyme Communications
Tel: +44(0)7920 770 935
Email: ben.rutter@zymecommunications.com

Domainex media contact:
Juliette Craggs / Maria Taylor
Sciad Communications Ltd.
Tel: +44 (0)2034 057892
Email: Domainex@sciad.com

Notes for Editors

About Nuclera

Nuclera’s mission is to better human health by enabling scientists to easily access the proteins they need for drug discovery research. The Company’s eProtein Discovery™ benchtop system accelerates protein expression and purification optimization in research labs, particularly those using AI including ML for protein design.

Applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery enables rapid, scalable access to high-quality proteins, supporting both cell-free and cell-based expression methods. The system significantly reduces time and cost of these processes by automating construct screening, protein scale-up, and producing purified proteins for downstream functional testing in under 48 hours. The system accelerates workflows, achieving results in days rather than the months required by traditional cell-based methods.

Founded in 2013, Nuclera’s offices are located in Cambridge (UK) and Boston (US).

For more information please visit: www.nuclera.com

About Domainex

Based in Cambridge, UK, Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organizations worldwide. The Company has been setting new standards in research since 2001, collaboratively with pharmaceutical and biotechnology companies, patient foundations, and leading academic institutions globally.

Domainex provides innovative and customized biology and chemistry services to advance its partners’ disease research projects, from target expression to pre-clinical development candidate nomination. Domainex leverages its considerable knowledge of drug discovery to provide intellectual input, creativity, and innovation to maximize the chance of successfully identifying drug candidates to treat debilitating diseases. Domainex works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how, and a wealth of experience to bear on their projects.

Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs.

Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.